HB1627, the TREATS Act, would amend the Controlled Substances Act to expand telehealth options for treating substance use disorders. Under current law, certain controlled substances generally require at least one in-person medical evaluation before they can be prescribed. This bill would create an additional pathway for FDA-approved Schedule III, IV, or V medications used to treat substance use disorder by allowing one telehealth evaluation to satisfy that requirement.
The bill defines telehealth evaluation broadly enough to include remote medical evaluations conducted in compliance with federal and state law, using telecommunications systems that support either audio-only or audio-video, real-time interaction between the practitioner and the patient. It applies to practitioners other than pharmacists and is aimed specifically at substance use disorder treatment medications, rather than changing telehealth prescribing rules across all controlled substances.
Impact
If enacted, the bill would amend 21 U.S.C. 829(e)(2) in the Controlled Substances Act to carve out a telehealth-based evaluation option for certain FDA-approved addiction treatment medications in Schedules III through V. This would reduce the need for an initial in-person visit for those prescriptions, potentially expanding access to medication-assisted treatment, especially for patients in rural areas, people with transportation barriers, and others with limited access to addiction specialists. It would also preserve the role of federal and state law compliance and would not eliminate in-person evaluation requirements generally for other controlled substances.
Sentiment
The available context suggests generally favorable treatment of the bill, or at least a policy direction aimed at expanding access to care through telehealth. The bill was introduced by bipartisan sponsors and referred to committee, but there are no recorded committee transcripts or votes in the provided material to show formal opposition or support. The framing of the legislation indicates an emphasis on practical access to substance use disorder treatment and modernizing prescribing rules.
Contention
The main policy tension is between expanding access to addiction treatment and maintaining safeguards around controlled substance prescribing. Supporters are likely to favor telehealth flexibility for patients who cannot easily obtain in-person care, while critics may be concerned about diversion, misuse, or reduced clinical oversight when controlled substances are prescribed remotely. The bill attempts to address those concerns by limiting the telehealth exception to FDA-approved Schedule III, IV, or V medications for substance use disorder treatment and by requiring compliance with applicable federal and state laws.
Revises telehealth and telemedicine requirements concerning adult prescription of certain Schedule II drugs for treatment of attention-deficit/hyperactivity disorder.